Short Interest in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Expands By 5.8%

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPHGet Free Report) saw a large growth in short interest in January. As of January 15th, there was short interest totalling 2,940,000 shares, a growth of 5.8% from the December 31st total of 2,780,000 shares. Approximately 8.2% of the company’s stock are short sold. Based on an average trading volume of 455,100 shares, the days-to-cover ratio is currently 6.5 days.

Analyst Ratings Changes

Several research firms recently weighed in on AMPH. StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 23rd. Bank of America initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 17th. They issued a “neutral” rating and a $63.00 target price for the company.

Check Out Our Latest Research Report on Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Trading Up 0.2 %

AMPH stock opened at $53.49 on Friday. The company has a debt-to-equity ratio of 1.07, a current ratio of 2.11 and a quick ratio of 1.68. The company has a fifty day moving average price of $57.75 and a two-hundred day moving average price of $53.96. Amphastar Pharmaceuticals has a one year low of $30.41 and a one year high of $67.66. The stock has a market cap of $2.56 billion, a price-to-earnings ratio of 20.89, a price-to-earnings-growth ratio of 0.69 and a beta of 0.93.

Amphastar Pharmaceuticals (NASDAQ:AMPHGet Free Report) last released its quarterly earnings data on Wednesday, November 8th. The company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.41. Amphastar Pharmaceuticals had a net margin of 22.50% and a return on equity of 26.68%. The firm had revenue of $180.56 million during the quarter, compared to analysts’ expectations of $170.65 million. Equities analysts anticipate that Amphastar Pharmaceuticals will post 2.91 EPS for the current year.

Insider Transactions at Amphastar Pharmaceuticals

In other news, Director Richard K. Prins sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $52.50, for a total transaction of $262,500.00. Following the completion of the transaction, the director now directly owns 35,895 shares of the company’s stock, valued at approximately $1,884,487.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Floyd F. Petersen sold 500 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $57.90, for a total value of $28,950.00. Following the completion of the transaction, the director now directly owns 81,333 shares of the company’s stock, valued at $4,709,180.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Richard K. Prins sold 5,000 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $52.50, for a total transaction of $262,500.00. Following the completion of the transaction, the director now directly owns 35,895 shares of the company’s stock, valued at $1,884,487.50. The disclosure for this sale can be found here. Insiders sold 282,860 shares of company stock valued at $16,055,773 in the last ninety days. 28.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 1.1% during the third quarter. BlackRock Inc. now owns 7,147,813 shares of the company’s stock worth $200,854,000 after buying an additional 75,616 shares in the last quarter. Federated Hermes Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 0.7% during the first quarter. Federated Hermes Inc. now owns 3,487,430 shares of the company’s stock worth $125,199,000 after buying an additional 23,095 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 1.8% during the third quarter. Vanguard Group Inc. now owns 2,606,162 shares of the company’s stock worth $73,234,000 after buying an additional 45,385 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Amphastar Pharmaceuticals by 0.7% during the second quarter. Dimensional Fund Advisors LP now owns 1,930,615 shares of the company’s stock worth $110,948,000 after buying an additional 13,044 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of Amphastar Pharmaceuticals by 16.6% during the second quarter. State Street Corp now owns 1,540,846 shares of the company’s stock worth $53,606,000 after buying an additional 218,895 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

(Get Free Report)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).

See Also

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.